While the reason for menopause remains unknown, KV Pharmaceutical believes EvaMist, which takes the third spot on the list, may offer significant advantages to women experiencing menopause. This product is a small, easy-to- use hand-held applicator that delivers a pre-set metered dose via the skin, releasing estradoil into the bloodstream over 24 hours. EvaMist gained FDA approval in July 2007.
The first of two potential treatments for cancer on the list of notable drugs gaining approval this quarter is Yondelis, developed by PharmaMar for patients who have not responded to previous regimens in their treatment of soft tissue sarcoma. Yondelis is the first approved product from PharmaMar, a Spanish biotech specializing in cancer drugs derived from marine organisms and has Orphan Drug status in both the EU and U.S., securing extended protection against generic competition.
The second approval win for Novartis this quarter, Tasigna, is an
orally available inhibitor of Bcr-Abl, c-Kit, PDGF-R and related receptor
tyrosine kinases for the potential treatment of various types of leukemia.
Though the drug has been approved only in Switzerland for chronic myeloid
leukemia, it is awaiting approval in the U.S. and Japan and has been
recommended for approval across the EU.
Following are the top five drugs in each category of phase changes:
The Five Most Promising Drugs Entering Phase III Trials
* bevasiranib sodium, (Wet AMD), Opko
* recombinant active glucocerebrosidase, (Gaucher's disease), Protalix
* odanacatib, (osteoporosis), Merck & Co
* laquinimod, (multiple sclerosis), Active Biotech/Teva
* elesclomol, (solid tumors), Synta
|SOURCE Thomson Scientific|
Copyright©2007 PR Newswire.
All rights reserved